Subscribe: MedWorm: Incretin Therapy
http://www.medworm.com/rss/medicalfeeds/therapies/Incretin-Therapy.xml
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
byetta  cancer  diabetes  drugs  incretin based  incretin  medpage today  pancreatic cancer  pancreatic  prweb  source  today 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: MedWorm: Incretin Therapy

MedWorm: Incretin Therapy News



MedWorm.com provides a medical RSS filtering service. Thousands of medical RSS feeds are combined and output via different filters. This feed contains the latest news in Incretin Therapy



Last Build Date: Thu, 22 Mar 2018 15:40:44 +0100

 



Incretin Tied to Better Outcomes in NOCS - Diabetes

Sat, 28 Oct 2017 00:00:00 +0100

Prognosis for T2DM patients with NSTEMI, coronary artery stenosis improves with incretin (Source: Pulmonary Medicine News - Doctors Lounge)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




International Harrington Prize in Medicine jointly awarded to three recipients

Tue, 14 Mar 2017 04:00:00 +0100

(University Hospitals Cleveland Medical Center) The fourth annual Harrington Prize for Innovation in Medicine has been jointly awarded to Daniel J. Drucker, MD (Mount Sinai Hospital, Canada), Joel F. Habener, MD (Massachusetts General Hospital, USA) and Jens J. Holst, MD, DMSc (University of Copenhagen, Denmark) for their discovery of incretin hormones and for the translation of these findings into transformative therapies for major metabolic diseases such as diabetes. (Source: EurekAlert! - Medicine and Health)



Diabetes could be a warning sign of pancreatic cancer

Tue, 31 Jan 2017 00:00:00 +0100

Conclusion This study uses a large prescription database to investigate the link between diabetes and pancreatic cancer, looking at the timing of first diabetes prescription and change in drugs prescribed. Among people with type 2 diabetes, diagnosis of pancreatic cancer was linked with recent onset of diabetes or rapidly deteriorating diabetes. This suggests these could both be potential warning signs of hidden pancreatic cancer and indicate the need for more investigations. While diabetes has previously been linked with pancreatic cancer, the nature of the cause and effect relationship remains unclear. It could be that diabetes increases risk of the cancer, or it could be that recent onset or deterioration of diabetes is a symptom of the cancer. It had also previously been thought that i...



[Report] Drosophila insulin release is triggered by adipose Stunted ligand to brain Methuselah receptor

Thu, 29 Sep 2016 22:00:00 +0100

Animals adapt their growth rate and body size to available nutrients by a general modulation of insulin–insulin-like growth factor signaling. In Drosophila, dietary amino acids promote the release in the hemolymph of brain insulin-like peptides (Dilps), which in turn activate systemic organ growth. Dilp secretion by insulin-producing cells involves a relay through unknown cytokines produced by fat cells. Here, we identify Methuselah (Mth) as a secretin-incretin receptor subfamily member required in the insulin-producing cells for proper nutrient coupling. We further show, using genetic and ex vivo organ culture experiments, that the Mth ligand Stunted (Sun) is a circulating insulinotropic peptide produced by fat cells. Therefore, Sun and Mth define a new cross-organ circuitry that modula...



Two incretin-based drugs linked to increased bile duct disease but not pancreatitis

Mon, 01 Aug 2016 15:00:00 +0100

At least two incretin-based drugs – glucagon-like peptide 1 agonists and dipeptidyl peptidase 4 inhibitors – do not appear to increase the risk of acute pancreatitis in individuals with diabetes but... (Source: Clinical Endocrinology News)



Monthly News Roundup - July 2016

Sun, 31 Jul 2016 02:08:45 +0100

Injectable Adlyxin FDA-Approved for Type 2 Diabetes The FDA has approved Sanofi’s Adlyxin (lixisenatide), a new once-daily injectable type 2 diabetes medication. Adlyxin is classified as an incretin mimetic/GLP-1 receptor agonist. For... (Source: Drugs.com - Pharma News)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Do artificial sweeteners live up to the promise of sweetness without harm? An ongoing clinical study investigates

Thu, 02 Jun 2016 16:15:23 +0100

Scientists suspect that aspartame and other artificial sweeteners can lead to lasting, metabolic disruptions when consumed frequently, by activating specific receptors in the intestine. A clinical study is now enrolling volunteer soda drinkers to test the hypothesis. More » (Source: The Rockefeller University Newswire)



No increased heart failure with incretin-based drugs

Thu, 24 Mar 2016 17:34:12 +0100

Incretin-based drugs, a type of medication used to treat type 2 diabetes, do not increase the risk of being hospitalized for heart failure relative to commonly used combinations of oral anti-diabetic drugs, according to a new study. (Source: ScienceDaily Headlines)



Incretin-Based Diabetes Drugs Not Tied to Heart Failure Hospitalizations (FREE)

Wed, 23 Mar 2016 23:00:00 +0100

By Kelly Young Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, FASAM Use of incretin-based drugs for type 2 diabetes — including dipeptidyl-peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 analogues — is not associated with increased risk for … (Source: Physician's First Watch current issue)



Incretin-based diabetes drugs don’t raise heart failure risk

Wed, 23 Mar 2016 21:00:00 +0100

Incretin-based antidiabetic drugs didn’t raise the risk of hospitalization for heart failure in an international observational study involving 1.5 million patients reported online March 24 in the New... (Source: Clinical Endocrinology News)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




GLP-1 and Hormonal Secretion in Posttransplant DiabetesGLP-1 and Hormonal Secretion in Posttransplant Diabetes

Thu, 17 Mar 2016 18:30:51 +0100

The incretin hormone glucagon-like peptide 1 (GLP-1) appears to correct the abnormal secretion of insulin and glucagon in posttransplantation diabetes (PTDM), researchers from Norway and Denmark report. Reuters Health Information (Source: Medscape Transplantation Headlines)



New Data Inform but Don't Confirm Incretin Diabetes Drugs SafetyNew Data Inform but Don't Confirm Incretin Diabetes Drugs Safety

Thu, 25 Feb 2016 09:10:34 +0100

Two new studies find that incretin-based drugs for the treatment of type 2 diabetes don't cause pancreatic cancer in the short term, but some may raise the risk of heart failure. Medscape Medical News (Source: Medscape Diabetes Headlines)



New incretin-based medicines will allow weight, diabetes control with a single weekly dose

Wed, 28 Oct 2015 09:49:22 +0100

The new generation of incretin-based medicines will allow a coordinated action against the combination diabetes/obesity, also known as diabesity, in some cases with only a single weekly dose, and with the likelihood of additional beneficial effects on other health complications related to this condition, such as cardiovascular and neurodegenerative diseases. (Source: ScienceDaily Headlines)



News from the European Association for the Study for Diabetes (EASD) conference in Stockholm

Thu, 17 Sep 2015 12:00:00 +0100

Women exposed to organic pollutants in early pregnancy have more than four-times increased risk of gestational diabetes New research presented at this year's annual meeting of the European Association for the Study of Diabetes in Stockholm shows that a 10-times increased exposure to organic pollutants in early pregnancy is associated with a 4.4 times increased risk of a pregnant woman developing gestational diabetes. Medical Xpress Pesticide exposure tied to diabetes risk A review of 21 observational studies has investigated the link between exposure to pesticides and diabetes. WebMD 'Youngest' toddler with type 2 diabetes raises concern The case of a 35kg-weighing 3-year old child recently diagnosed with type-2 diabetes is being discussed today at the EASD c...



Study Suggests Incretin Drugs Don't Cause Pancreatic CancerStudy Suggests Incretin Drugs Don't Cause Pancreatic Cancer

Tue, 15 Sep 2015 21:08:45 +0100

A 7-year Danish population-based study found pancreatic cancer risks elevated for all glucose-lowering agents, not just incretin-based therapies, suggesting that diabetes itself may be the cause. Medscape Medical News (Source: Medscape Medical News Headlines)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Incretin-Based Therapies and Cardiovascular DiseaseIncretin-Based Therapies and Cardiovascular Disease

Fri, 29 May 2015 10:50:45 +0100

Incretin-based therapies offer another treatment option for patients with type 2 diabetes, and may have a beneficial effect on cardiovascular risk factors. International Journal of Clinical Practice (Source: Medscape Today Headlines)



Danish Study: No Excess Pancreatitis Risk in Incretin UsersDanish Study: No Excess Pancreatitis Risk in Incretin Users

Mon, 09 Feb 2015 14:22:01 +0100

Researchers found that users of all diabetes drug classes had elevated pancreatitis rates, which became nonsignificant after adjustment for confounders. Medscape Medical News (Source: Medscape Diabetes Headlines)



Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics...

Mon, 22 Dec 2014 09:20:07 +0100

Hundreds of Byetta lawsuits and other product liability claims involving incretin mimetic diabetes drugs are currently pending in the federal litigation underway in California.(PRWeb December 21, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12409444.htm (Source: PRWeb: Medical Pharmaceuticals)



Basal Insulin With Incretin GLP-1 Receptor Agonists for T2DMBasal Insulin With Incretin GLP-1 Receptor Agonists for T2DM

Mon, 15 Dec 2014 14:02:26 +0100

These tools can help guide the combined use of basal insulin with GLP-1 receptor agonists. Therapeutic Advances in Endocrinology and Metabolism (Source: Medscape Today Headlines)



Diabetes Drug Litigation Prepares to Discuss Byetta Lawsuits, Claims...

Sun, 07 Dec 2014 18:55:08 +0100

The Firm is evaluating Byetta lawsuits and other product liability claims on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer caused by incretin mimetic...(PRWeb December 07, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12376827.htm (Source: PRWeb: Medical Pharmaceuticals)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




New Order Issued in Federal Incretin Mimetic Litigation, Where...

Tue, 02 Dec 2014 13:15:09 +0100

The Firm is evaluating Byetta lawsuits and other product liability claims on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer caused by incretin mimetic...(PRWeb December 01, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12363707.htm (Source: PRWeb: Medical Pharmaceuticals)



California Federal Court Overseeing Byetta Lawsuits, Other Incretin...

Sun, 23 Nov 2014 12:10:12 +0100

The Firm is evaluating Byetta lawsuits and other product liability claims on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer after taking incretin...(PRWeb November 23, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12344447.htm (Source: PRWeb: Medical Pharmaceuticals)



Byetta Lawsuit News: Plaintiffs in Federal Diabetes Drug Litigation...

Wed, 12 Nov 2014 23:00:11 +0100

The Firm is evaluating Byetta lawsuits and other product liability claims that allege incretin mimetic diabetes drugs caused patients to develop pancreatic cancer, pancreatitis and thyroid cancer.(PRWeb November 11, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12318604.htm (Source: PRWeb: Medical Pharmaceuticals)



Diabetes Drug Claims Near 550 Mark in Incretin Mimetic Litigation,...

Sun, 02 Nov 2014 13:55:08 +0100

The Firm is investigating Byetta lawsuits and other legal claims that allege pancreatic cancer, pancreatitis and thyroid cancer caused by incretin mimetics, a Type 2 diabetes drug class.(PRWeb November 02, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12294498.htm (Source: PRWeb: Medical Pharmaceuticals)



Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics...

Thu, 09 Oct 2014 10:20:09 +0100

The Firm is evaluating Byetta lawsuits and other legal claims that allege the use of diabetes drugs called incretin mimetics caused patients to develop pancreatic cancer, pancreatitis or thyroid...(PRWeb October 08, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12234584.htm (Source: PRWeb: Medical Pharmaceuticals)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Byetta Lawsuits Move Forward, With New Ruling Issued in Federal...

Thu, 25 Sep 2014 21:50:05 +0100

The Firm is evaluating Byetta lawsuits and other product liability claims that allege incretin mimetic diabetes drugs caused patients to develop pancreatic cancer, pancreatitis and thyroid cancer.(PRWeb September 24, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12196939.htm (Source: PRWeb: Medical Pharmaceuticals)



Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics...

Fri, 12 Sep 2014 11:30:08 +0100

The Firm is evaluating Byetta lawsuits on behalf of individuals who developed pancreatitis, pancreatic cancer or thyroid cancer allegedly due to their use of Byetta or other incretin mimetic Type 2...(PRWeb September 11, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12163899.htm (Source: PRWeb: Medical Pharmaceuticals)



Byetta Lawsuit News: New Order Establishes Deposition Protocol For...

Sun, 10 Aug 2014 17:30:08 +0100

The Firm is investigating Byetta lawsuits and other legal claims that allege incretin mimetics like Byetta, Januvia and Victoza caused patients to develop pancreatic cancer, pancreatitis or thyroid...(PRWeb August 10, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12083571.htm (Source: PRWeb: Medical Pharmaceuticals)



Diabetes Drug Eyed as Obesity TreatmentDiabetes Drug Eyed as Obesity Treatment

Mon, 26 May 2014 19:05:38 +0100

Already approved for the treatment of diabetes, the incretin mimetic liraglutide is now being investigated as a potential weight-loss drug. Medscape Medical News (Source: Medscape Medical News Headlines)



Featured in NEJM Journal Watch: Incretin-Based Diabetes Drugs Aren't Associated with Excess Risk for Acute Pancreatitis (FREE)

Thu, 08 May 2014 00:00:00 +0100

Extract Although not the final word, results of two large studies in BMJ should be reassuring for patients taking exenatide (Byetta) and sitagliptin (Januvia... (Source: Physician's First Watch current issue)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Incretin-Targeting Diabetic Drugs: FDA & EMA See No Apparent Pancreatic Harms (FREE)

Fri, 28 Feb 2014 00:00:00 +0100

By Joe Elia Drugs targeting the insulin-releasing effects of the hormone incretin, such as exenatide (Byetta) and sitagliptin (Januvia), cause no apparent increase in pancreatic side effects, according to a … (Source: Physician's First Watch current issue)



As Byetta Lawsuits Move Forward, Bernstein Liebhard LLP Notes New FDA...

Fri, 14 Feb 2014 11:20:06 +0100

The Firm is evaluating Byetta lawsuits and other legal claims on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis, and thyroid cancer due their use of incretin mimetic...(PRWeb February 13, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb11583185.htm (Source: PRWeb: Medical Pharmaceuticals)



Byetta Lawsuits Move Forward, as Federal and State Incretin Mimetics...

Sat, 25 Jan 2014 14:35:05 +0100

The Firm is investigating Byetta lawsuits that allege an association between the use of Byetta and pancreatic cancer, as well as pancreatitis and thyroid cancer.(PRWeb January 25, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb11521828.htm (Source: PRWeb: Medical Pharmaceuticals)



The Cardiovascular Safety of Incretin-Based TherapiesThe Cardiovascular Safety of Incretin-Based Therapies

Mon, 02 Dec 2013 05:27:39 +0100

Do controlled trials find that 'gliptins' increase risk for adverse cardiac events? Cardiovascular Diabetology (Source: Medscape Today Headlines)



Incretin Safety Data to Highlight EASD Meeting

Fri, 20 Sep 2013 21:13:01 +0100

BARCELONA (MedPage Today) -- Researchers are anticipating a deeper dive into data from safety trials of two DPP-4 inhibitors with a focus on diabetes outcomes and complications, including pancreatitis, at this year's European Association for the Study of Diabetes meeting here. (Source: MedPage Today Endocrinology)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Cardiac Risks of Diabetes Drugs a Focus at EASD

Thu, 19 Sep 2013 22:13:02 +0100

BARCELONA (MedPage Today) -- A major focus of the upcoming meeting of the European Association for the Study of Diabetes here will be the risks and benefits of the incretin-based therapies, according to the chair of the program committee. (Source: MedPage Today Cardiovascular)



Novel Diabetes Drug Effective in Trial (CME/CE)

Tue, 10 Sep 2013 18:30:00 +0100

(MedPage Today) -- The investigational SGLT2 inhibitor empagliflozin lowers HbA1c as well as the widely used DPP-4 inhibitor sitagliptin (Januvia), and may work better than the incretin stimulator among patients with worse disease control, researchers found. (Source: MedPage Today Endocrinology)



Incretin Risks Lack Evidence, Says AACE

Thu, 22 Aug 2013 22:13:00 +0100

(MedPage Today) -- There currently is insufficient evidence of a definitive link between incretin diabetes medications and an increased risk of cancer, according to a consensus statement from the American Association of Clinical Endocrinologists. (Source: MedPage Today Cardiovascular)



The Safety of Incretin Therapy: Are Barriers Beginning to Fall?

Sat, 03 Aug 2013 11:00:02 +0100

The European Medicines Agency declared in July 2013 that there is no evidence that definitively links incretin-based therapy for type 2 diabetes and pancreatitis or pancreatic cancer. Today, August 2, 2013, there are rumors that the US FDA "concurs." (Source: Consultant Live)



FDA Sides With EMA on Incretin Diabetes DrugsFDA Sides With EMA on Incretin Diabetes Drugs

Fri, 02 Aug 2013 00:18:23 +0100

The FDA agrees with the EMA's recent conclusions that firm data lacks support for an increased risk for pancreatic adverse effects with incretin mimetics. Medscape Medical News (Source: Medscape Today Headlines)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




EMA Finds No Pancreas Risks with Incretins

Mon, 29 Jul 2013 16:41:47 +0100

(MedPage Today) -- The European Medicines Agency has cleared incretin drugs for type 2 diabetes of an association with pancreatic risks. (Source: MedPage Today Cardiovascular)



EU agency has no new concerns about incretin diabetes drugs

Fri, 26 Jul 2013 15:15:00 +0100

Current data do not confirm recent concerns over an increased risk of pancreatic adverse events with GLP-1-based type 2 diabetes drugs, says the European Medicines Agency. (Source: theHeart.org)



EU Agency Has No New Concerns on Incretin Diabetes Drugs EU Agency Has No New Concerns on Incretin Diabetes Drugs

Fri, 26 Jul 2013 13:30:08 +0100

Current data do not confirm recent concerns over an increased risk for pancreatic adverse events with GLP-1-based type 2 diabetes drugs, says the European Medicines Agency. Medscape Medical News (Source: Medscape Today Headlines)



Merck Statement Regarding CHMP Review of Incretin-Based Therapies for Type 2 Diabetes, Including Sitagliptin

Fri, 26 Jul 2013 13:15:00 +0100

Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, issued the following statement regarding the conclusion of the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) review of GLP-1, or incretin-based, therapies, including sitagliptin. Language:  English Contact:  MerckMedia:Pam Eisele, 908-423-5042Mary Elizabeth Blake, 908-423-5550orInvestors:Carol Ferguson, 908-423-4465 Ticker Slug:  Ticker: MRK Exchange: NYSE read more (Source: Merck.com - Research and Developme...



Merck's $5.7 Billion Diabetes Franchise Vulnerable

Tue, 23 Jul 2013 19:55:00 +0100

A retrospective analysis published by the BMJ supports previously published findings that diabetic patients taking drugs which target the incretin system to control their blood sugars are at greater risk for developing pancreatic problems, such as acute pancreatitis and pancreatic cancer. Could certain big pharma manufacturers be vulnerable to a price collapse, should European and U.S. regulators ? whom are now actively reviewing data on adverse events ? move to restrict usage or outright remove these therapies from the market due to questionable safety? (Source: Forbes.com Healthcare News)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




"Breakthrough" Incretin Mimetic Drugs May Cause Pancreatic...

Tue, 09 Jul 2013 02:15:18 +0100

New website offers information about the startling link between incretin mimetics, which are used to treat type two diabetes, and serious illnesses such as renal insufficiency and pancreatic cancer.(PRWeb July 07, 2013)Read the full story at http://www.prweb.com/releases/2013/7/prweb10895062.htm (Source: PRWeb: Medical Pharmaceuticals)



More Calls for More Research on Incretin Diabetes DrugsMore Calls for More Research on Incretin Diabetes Drugs

Mon, 24 Jun 2013 16:29:06 +0100

The Endocrine Society is the latest organization to call for more research into incretin-based therapies for diabetes and their possible association with pancreatic cancer. Medscape Medical News (Source: Medscape Today Headlines)



ENDO Seconds Call for Incretin Data

Wed, 19 Jun 2013 15:46:12 +0100

SAN FRANCISCO (MedPage Today) -- The Endocrine Society has joined its voice to the recent call for incretin drugmakers to release all patient-level data on their products, the group announced at its annual meeting. (Source: MedPage Today Cardiovascular)



Society Seconds Call for Incretin Data

Wed, 19 Jun 2013 15:30:15 +0100

SAN FRANCISCO (MedPage Today) -- The Endocrine Society has joined its voice to the recent call for incretin drugmakers to release all patient-level data on their products, the group announced at its annual meeting. (Source: MedPage Today Cardiovascular)



Incretin Talk Continues at ENDO Meeting

Fri, 14 Jun 2013 19:13:00 +0100

SAN FRANCISCO (MedPage Today) -- As the debate over pancreatic risks with incretin therapies for type 2 diabetes comes to a boil, it's likely to be the topic of much discussion at this year's meeting of the Endocrine Society. (Source: MedPage Today Cardiovascular)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Pancreatic Cancer and Incretins: No Signal as Yet at NIDDKPancreatic Cancer and Incretins: No Signal as Yet at NIDDK

Fri, 14 Jun 2013 14:48:01 +0100

A definitive answer on whether there is an increased risk of pancreatic cancer with incretin diabetes drugs is still some years away, said dozens of experts at the NIDDK this week. Medscape Medical News (Source: Medscape Today Headlines)



ADA Wants Firms to Disclose Incretin Data

Thu, 13 Jun 2013 22:13:00 +0100

(MedPage Today) -- The American Diabetes Association is calling for makers of incretin therapies to release all of their data on the drugs in an effort to clarify whether they have adverse effects on the pancreas, the group said. (Source: MedPage Today Cardiovascular)



BMJ Examines Risks of Incretin Therapy

Wed, 12 Jun 2013 22:13:01 +0100

(MedPage Today) -- Incretin mimetics may be more risky than previously thought, given that drug companies have held back data on their potentially harmful effects, says the BMJ. (Source: MedPage Today Cardiovascular)



Merck Welcomes Independent Review of the Safety Profile of JANUVIA® (sitagliptin) and Other Diabetes Medicines

Wed, 12 Jun 2013 12:00:00 +0100

Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, today issued the following statement regarding this week's NIDDK-NCI Workshop and the American Diabetes Association’s (ADA) call for an independent review of data about the safety of incretin-based diabetes medicines, including GLP-1 analogs and DPP-4 inhibitors such as JANUVIA® (sitagliptin). Language:  English Contact:  MerckMedia:Pam Eisele(267) 664-0282orKim Hamilton(908) 391-0131orInvestor:Carol Ferguson(908) 423-4465 Ticker Slug:  Ticker: MRK Ex...



Effects of GLP1R agonists on primary thyroid C-cells

Wed, 12 Jun 2013 12:00:00 +0100

Glucagon-like peptide 1 (GLP1) is an incretin hormone that promotes glucose-dependent stimulation of insulin and suppression of glucagon secretion, delays gastric emptying, and reduces energy intake. GLP1 also increases β-cell mass via stimulation of β-cell proliferation. The actions of GLP1 are mediated by a GLP1 receptor (GLP1R). Boess et al. aimed to establish primary thyroid cell cultures of rat and human to evaluate the expression and function of GLP1R in C-cells as functional C-cell response has rarely been demonstrated. They  succeeded in establishing primary thyroid cell culture systems for rat and human tissue and present data  on the expression of GLP1R, and on the functional response of the cultures toward the GLP1R agonists liraglutide and ...

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Diabetes drugs may be linked to pancreatic cancer

Mon, 10 Jun 2013 10:14:00 +0100

Conclusion This article presents important concerns that glucagon-like peptide-1 (GLP-1) agonists and dipeptidylpeptidase-4 (DPP-4) inhibitors could potentially increase the risk of inflammation and cancerous changes in the pancreas. The agencies that regulate medicines in Europe and the USA are aware of these issues, and told the BMJ that their analyses show increased reporting of pancreatic cancer among people taking these types of drugs. However, the agencies note that it has not been established whether these drugs directly cause the adverse effects seen in the pancreas. Both agencies are reviewing emerging evidence on safety in this area. For now, anyone with diabetes who has been prescribed these drugs and has concerns should speak with the healthcare professionals involved in...



Researchers Face Off Over Incretin Risk

Fri, 17 May 2013 20:07:20 +0100

(MedPage Today) -- As concerns escalate over the potential risks of glucagon-like peptide-1 (GLP-1)-based therapies, a diabetes journal hosted a point-counterpoint debate between the researchers who have been the leading voices on each side of the issue. (Source: MedPage Today Cardiovascular)



Safety of Incretin-Based Therapies Hotly Debated Safety of Incretin-Based Therapies Hotly Debated

Wed, 08 May 2013 22:26:24 +0100

Should clinicians worry about possible cancer risks with incretin mimetic drugs for type 2 diabetes? Yes, say some experts. No, says another, arguing that substantial evidence is lacking. Medscape Medical News (Source: Medscape Cardiology Headlines)



Report Shows Byetta, Januvia and Other Incretin Mimetic Drugs for Type...

Tue, 23 Apr 2013 07:10:17 +0100

According to the Institute for Safe Medication Practices’ most recent QuarterWatch report, incretin mimetic drugs such as Byetta, Januvia and Victoza may be 25 times more likely to be linked to...(PRWeb April 19, 2013)Read the full story at http://www.prweb.com/releases/Byetta-Januvia-cancer/04/prweb10653663.htm (Source: PRWeb: Medical Pharmaceuticals)



Exendin-4 prevents lipoapoptosis

Thu, 11 Apr 2013 12:00:00 +0100

Type 2 diabetes and insulin resistance are associated with atherosclerosis, which is the major cause of morbidity and mortality in these patients. Experimental studies have indicated that endothelial cells play an important role in maintaining vascular homeostasis. Erdogdu et al. conducted a study to investigate the putative protective effect of exendin-4 (a stable incretin mimetic and GLP1 receptor agonist) and GLP1 against lipoapoptosis of HCAECs and attempt to address the pathways involved in imparting such an effect. They found that long-term exposure of HCAECs to palmitate induces apoptosis, eNOS activity, ROS release, and production of NO. Exendin-4 and GLP1 confer protection against this lipoapoptosis mediated through the GLP1 receptor involving PKA-, eNOS-, p38 MAPK-, and JNK-depen...

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Popular Diabetes Drugs May Harm The Pancreas

Mon, 01 Apr 2013 07:00:00 +0100

Type 2 diabetes patients who are on incretin therapy have a higher risk of developing abnormalities in their pancreas compared to their counterparts on other types of diabetes therapies, researchers from the Larry L. Hillblom Islet Research Center at UCLA and the Diabetes Center at the University of Florida reported in the journal Diabetes. The scientists explained that patients on incretin therapy were more likely to have rapid multiplication of pancreatic cells that may be associated with a higher risk of neuroendocrine tumors... (Source: Health News from Medical News Today)



EU Will Study Risks of Incretin Mimetics for DiabetesEU Will Study Risks of Incretin Mimetics for Diabetes

Wed, 27 Mar 2013 17:34:39 +0100

Like their US counterparts, European regulators will investigate the findings of a recent study suggesting an increased risk for precancerous cellular changes in the pancreas as well as pancreatitis. News Alerts (Source: Medscape Today Headlines)



Incretins Beef Up Pancreas (CME/CE)

Wed, 27 Mar 2013 16:26:33 +0100

(MedPage Today) -- Incretin therapy increased pancreatic mass and beta cell mass in patients with type 2 diabetes, potentially putting patients at risk for malignancies, researchers found. (Source: MedPage Today Cardiovascular)



Research suggests popular diabetes drugs can cause abnormal pancreatic growth in humans

Tue, 26 Mar 2013 14:30:00 +0100

Individuals who had taken a type of drug commonly used to treat Type 2 diabetes showed abnormalities in the pancreas, including cell proliferation, that may be associated with an increased risk of neuroendocrine tumors, according to a new study by researchers from UCLA and the University of Florida. Their findings were published online March 22 in the journal Diabetes.   The researchers, from the Larry L. Hillblom Islet Research Center at UCLA and the Diabetes Center at the University of Florida, found that cell mass was increased approximately 40 percent in the pancreases of deceased organ donors who had Type 2 diabetes and who had been treated with incretin therapy. This widely used type of treatment takes advantage of the action of a gut hormone known as glucagon-like pep...



FDA Probing Risk of Pancreatitis with Incretins

Thu, 14 Mar 2013 21:43:01 +0100

(MedPage Today) -- The FDA said Thursday it is reviewing unpublished data that point toward an increased risk of pancreatitis and precancerous changes in type 2 diabetes patients who are treated with drugs in the incretin class. (Source: MedPage Today Cardiovascular)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




FDA to Examine Pancreatic-Duct Metaplasia With IncretinsFDA to Examine Pancreatic-Duct Metaplasia With Incretins

Thu, 14 Mar 2013 18:53:25 +0100

The FDA has issued a drug safety communication alerting patients and doctors to a possible association between incretin mimetic diabetes drugs and precancerous changes in the pancreas. News Alerts (Source: Medscape Today Headlines)



Incretin Mimetic Drugs for Type 2 Diabetes: Early Communication - Reports of Possible Increased Risk of Pancreatitis and Pre-cancerous Findings of the Pancreas

Thu, 14 Mar 2013 06:45:00 +0100

Unpublished new findings by a group of academic researchers suggest an increased risk of pancreatitis and pre-cancerous cellular changes called pancreatic duct metaplasia. (Source: FDA MedWatch)



DPP-4 Antagonists: Benefits, Risks, and the Future

Mon, 25 Feb 2013 12:00:00 +0100

Dipeptidyl peptidase-4 inhibitors, of the incretin class of antidiabets drugs, are weight neutral, avoid hypoglycemia, and result in an average reduction in HbA1c of 0.5% to 1.0%. Here, an expert on the DPP-4s and their evolution discusses pros and cons. (Source: Consultant Live)